A consortium of VCs, investment firms and strategic investors have taken part in a Deerfield Management-led $150m series-C funding round for UK- and US-based gene therapy developer Orchard Therapeutics.
Shares are sold by shares were held by CapMan Buyout X Fund A and CapMan Buyout X Fund B
Advent made a takeover offer of 165 pence per share in cash, which represents a 34% premium in July
Business strategy platform will expand its product and triple its team size
Fund targets companies operating in the healthcare industry, primarily pharma, medtech and outsourced services